Celldex Positive Topline Results from Barzolvolimab Phase 2 Study in Urticaria

 Barzolvolimab met primary endpoint with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups-

-Mean change from baseline to week 12 in UAS7 of -23.87 in 300 mg q8w dose group and -23.02 in 150 mg q4w dose group-
-Barzolvolimab was generally well tolerated with a favorable safety profile-
-Treatment will continue to 52 weeks; results support further development of barzolvolimab in Phase 3 CSU studies-
- Company to host webcast call today at 8:00 am ET-

The Company will host a conference call/webcast today to discuss the results at 8:00 a.m. ET. The event will be webcast live and can be accessed by going to the "Events & Presentations " page under the "Investors & Media” section of the Celldex Therapeutics website at www.celldex.com. The call can also be accessed by dialing (646) 307-1963 or (800) 715-9871 (toll free). The conference ID is 3272134.

https://www.globenewswire.com/news-release/2023/11/06/2773880/24180/en/Celldex-Therapeutics-Announces-Positive-Topline-Results-from-Barzolvolimab-Phase-2-Study-in-Chronic-Spontaneous-Urticaria.html